Company: NYXH
Filing Date: 2025-08-11
Form Type: 6-K
Source: 0001104659-25-075831
Chunk: 4

Company: Nyxoah SA
Filing Date: 2025-08-11
Form: 6-K
Chunk 4
---
 our product candidates. Our failure to identify
and correctly interpret relevant patents may negatively impact our ability to develop and market the Genio system and our product candidates.

Any infringement claim against us, even if without
merit, may cause us to incur substantial costs, and could place a significant strain on our financial resources and/or divert the time
and efforts of management from the conduct of our business. For example, on May 30, 2025, the Company received notice that Inspire Medical
Systems, Inc. (“Inspire”) filed a lawsuit against the Company and Nyxoah, Inc., a Delaware corporation and wholly-owned subsidiary
of the Company, in the United States District Court for the District of Delaware, alleging that the Company’s Genio system infringes
certain patents owned by Inspire and seeks customary remedies for patent infringement. In addition to Inspire’s current claims of
infringement, our competitors or other third parties may in the future claim that we are infringing upon their intellectual property rights,
and we may be found to be infringing upon such rights.

Potential litigants, including some of our competitors
and patent-holding companies, have the ability to dedicate substantial resources to assert their intellectual property rights and to defend
claims that may be brought against them. In addition, any intellectual property litigation could force us to do one or more of the following:
(i) stop selling the Genio system or using technology that contains the allegedly infringing intellectual property; (ii) forfeit the opportunity
to license our patented technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual
property rights against others; (iii) pay substantial damages or ongoing royalty payments to the party whose intellectual property rights
we may be found to be infringing; or (iv) force us to implement expensive work-arounds, including redesigning those products that contain
or utilize the allegedly infringing intellectual property. In addition, we may be required to license additional technology from third
parties to develop and market new systems or technology, which may not be on commercially reasonable terms, or at all, and would adversely
affect our ability to compete. Any license or settlement entered into as the result of claims or litigation may not provide us with sufficient
rights to sell the Genio system. We also expect that the occurrence of infringement claims is likely to grow as the market for our technology
grows and as we introduce new and updated products and offerings. Accordingly, our exposure to damages resulting